we evaluate each contingent payment on an individual basis to determine whether they are considered substantive milestones , specifically reviewing factors such as the degree of certainty in achieving the milestone , the research and development risk and other risks that must be overcome to achieve the milestone , as well as the level of effort and investment required and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement . this evaluation includes an assessment of whether ( a ) the consideration is commensurate with either ( 1 ) the entity 's performance to achieve the milestone , or ( 2 ) the enhancement of the value of the delivered item ( s ) as a result of a specific outcome resulting from the entity 's performance to achieve the milestone , ( b ) the consideration relates solely to past performance and ( c ) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement . revenues from milestones , if they are nonrefundable and deemed substantive , are recognized upon achievement of the milestones . to the extent that non-substantive milestones are achieved , and we have remaining deliverables , milestone payments are deferred and recognized as revenue over the estimated remaining performance period using the appropriate measure of progress as determined for each agreement . we recognize revenue associated with the non-substantive milestones upon achievement of the milestone if we have no remaining deliverables . during the years ended november 30 , 2019 , no milestone payments were received , no milestone revenues were recognized and no milestones were considered substantive . effective december 1 , 2019 , we adopted topic 606 , revenue from contracts with customers using the modified retrospective method , which was only applied to contracts that were not completed as of the adoption date . as of the adoption date , we had only one contract , a collaboration agreement with gilead , not completed . under topic 606 , we recognize revenue when its customer obtains control of promised goods or services , in an amount that reflects the consideration which we expect to receive in exchange for those goods or services . to determine revenue recognition for arrangements that we determine are within the scope of topic 606 , we perform the following five steps : ( i ) identify the contract ( s ) with a customer ; ( ii ) identify the performance obligations in the contract ; ( iii ) determine the transaction price ; ( iv ) allocate the transaction price to the performance obligations in the contract ; and ( v ) recognize revenue when ( or as ) we satisfy a performance obligation . 102 at contract inception , we assess the goods or services promised within each contract , whether each promised good or service is distinct , and determines those that are performance obligations . we then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied . we enter into collaboration agreements under which we may obtain upfront payments , milestone payments , royalty payments and other fees . promises under these arrangements may include research licenses , research services , including selection campaign research services for certain replacement targets , the obligation to share information during the research and the participation of alliance managers and in joint research committees , joint patent committees and joint steering committees . we assess these promises within the context of the agreements to determine the performance obligations . research and collaboration licenses : if a license is determined to be distinct from the other promises identified in the arrangement , we recognize revenue from upfront payments allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license . for licenses that are bundled with other promises , we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and , if over time , the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable , upfront payments . we evaluate the measure of proportional performance each reporting period and , if necessary , adjusts the measure of performance and related revenue recognition . milestone payments : at the inception of each arrangement that includes research , development , or regulatory milestone payments , we evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price . we use the most likely amount method for research , development and regulatory milestone payments . under the most likely amount method , an entity considers the single most likely amount in a range of possible consideration amounts . if it is probable that a significant revenue reversal would not occur , the associated milestone amount is included in the transaction price . sales-based milestones and royalties : for arrangements that include sales-based milestone or royalty payments based on the level of sales , and in which the license is deemed to be the predominant item to which the sales-based milestone or royalties relate to , we recognize revenue in the period in which the sales-based milestone is achieved and in the period in which the sales associated with the royalty occur . to date , we have not recognized any sales-based milestone or royalty revenue resulting from our collaboration arrangements . customer options : customer options , such as options granted to allow a licensee to extend a license or research term , to select additional research targets or to choose to research , develop and commercialize licensed compounds are evaluated at contract inception to determine whether those options provide a material right ( story_separator_special_tag we evaluate each contingent payment on an individual basis to determine whether they are considered substantive milestones , specifically reviewing factors such as the degree of certainty in achieving the milestone , the research and development risk and other risks that must be overcome to achieve the milestone , as well as the level of effort and investment required and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement . this evaluation includes an assessment of whether ( a ) the consideration is commensurate with either ( 1 ) the entity 's performance to achieve the milestone , or ( 2 ) the enhancement of the value of the delivered item ( s ) as a result of a specific outcome resulting from the entity 's performance to achieve the milestone , ( b ) the consideration relates solely to past performance and ( c ) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement . revenues from milestones , if they are nonrefundable and deemed substantive , are recognized upon achievement of the milestones . to the extent that non-substantive milestones are achieved , and we have remaining deliverables , milestone payments are deferred and recognized as revenue over the estimated remaining performance period using the appropriate measure of progress as determined for each agreement . we recognize revenue associated with the non-substantive milestones upon achievement of the milestone if we have no remaining deliverables . during the years ended november 30 , 2019 , no milestone payments were received , no milestone revenues were recognized and no milestones were considered substantive . effective december 1 , 2019 , we adopted topic 606 , revenue from contracts with customers using the modified retrospective method , which was only applied to contracts that were not completed as of the adoption date . as of the adoption date , we had only one contract , a collaboration agreement with gilead , not completed . under topic 606 , we recognize revenue when its customer obtains control of promised goods or services , in an amount that reflects the consideration which we expect to receive in exchange for those goods or services . to determine revenue recognition for arrangements that we determine are within the scope of topic 606 , we perform the following five steps : ( i ) identify the contract ( s ) with a customer ; ( ii ) identify the performance obligations in the contract ; ( iii ) determine the transaction price ; ( iv ) allocate the transaction price to the performance obligations in the contract ; and ( v ) recognize revenue when ( or as ) we satisfy a performance obligation . 102 at contract inception , we assess the goods or services promised within each contract , whether each promised good or service is distinct , and determines those that are performance obligations . we then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied . we enter into collaboration agreements under which we may obtain upfront payments , milestone payments , royalty payments and other fees . promises under these arrangements may include research licenses , research services , including selection campaign research services for certain replacement targets , the obligation to share information during the research and the participation of alliance managers and in joint research committees , joint patent committees and joint steering committees . we assess these promises within the context of the agreements to determine the performance obligations . research and collaboration licenses : if a license is determined to be distinct from the other promises identified in the arrangement , we recognize revenue from upfront payments allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license . for licenses that are bundled with other promises , we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and , if over time , the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable , upfront payments . we evaluate the measure of proportional performance each reporting period and , if necessary , adjusts the measure of performance and related revenue recognition . milestone payments : at the inception of each arrangement that includes research , development , or regulatory milestone payments , we evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price . we use the most likely amount method for research , development and regulatory milestone payments . under the most likely amount method , an entity considers the single most likely amount in a range of possible consideration amounts . if it is probable that a significant revenue reversal would not occur , the associated milestone amount is included in the transaction price . sales-based milestones and royalties : for arrangements that include sales-based milestone or royalty payments based on the level of sales , and in which the license is deemed to be the predominant item to which the sales-based milestone or royalties relate to , we recognize revenue in the period in which the sales-based milestone is achieved and in the period in which the sales associated with the royalty occur . to date , we have not recognized any sales-based milestone or royalty revenue resulting from our collaboration arrangements . customer options : customer options , such as options granted to allow a licensee to extend a license or research term , to select additional research targets or to choose to research , develop and commercialize licensed compounds are evaluated at contract inception to determine whether those options provide a material right (

cash flows the following table summarizes our cash flows during the periods indicated : replace_table_token_4_th operating activities net cash used in operating activities was $ 0.1 million for the year ended november 30 , 2020 and consisted of a decrease in net assets of $ 36.4 million and non-cash adjustments of $ 6.8 million , offset by our net loss of $ 43.2 million . the decrease in net assets consisted primarily of an increase in deferred revenue of $ 48.2 million related to proceeds received pursuant to the sanofi agreement and offset by revenue recognized pursuant to the sanofi agreement and the gilead agreement . the decrease in net assets was offset by an increase in contract assets of $ 7.5 related to unbilled revenue for gilead milestones and an increase in income tax receivables of $ 3.9 million related to nol carryback claims as a result of the cares act . non-cash adjustments primarily consisted of stock-based compensation expenses of $ 4.3 million and depreciation and amortization expenses of $ 2.2 million . net cash provided by operating activities was $ 0.6 million for the year ended november 30 , 2019 and consisted of a decrease in net assets of $ 19.5 million and non-cash adjustments of $ 2.8 million , offset by our net loss of $ 21.7 million . the decrease in net assets consisted primarily of an increase in deferred revenue of $ 16.9 million related to $ 48.0 million in proceeds received pursuant to the gilead agreement and offset by $ 31.1 million in revenue recognized pursuant to the celgene agreement and the gilead agreement and an increase in accrued and other liabilities of $ 2.4 million primarily related to an increase in accrued compensation from higher incentive compensation .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows the following table summarizes our cash flows during the periods indicated : replace_table_token_4_th operating activities net cash used in operating activities was $ 0.1 million for the year ended november 30 , 2020 and consisted of a decrease in net assets of $ 36.4 million and non-cash adjustments of $ 6.8 million , offset by our net loss of $ 43.2 million . the decrease in net assets consisted primarily of an increase in deferred revenue of $ 48.2 million related to proceeds received pursuant to the sanofi agreement and offset by revenue recognized pursuant to the sanofi agreement and the gilead agreement . the decrease in net assets was offset by an increase in contract assets of $ 7.5 related to unbilled revenue for gilead milestones and an increase in income tax receivables of $ 3.9 million related to nol carryback claims as a result of the cares act . non-cash adjustments primarily consisted of stock-based compensation expenses of $ 4.3 million and depreciation and amortization expenses of $ 2.2 million . net cash provided by operating activities was $ 0.6 million for the year ended november 30 , 2019 and consisted of a decrease in net assets of $ 19.5 million and non-cash adjustments of $ 2.8 million , offset by our net loss of $ 21.7 million . the decrease in net assets consisted primarily of an increase in deferred revenue of $ 16.9 million related to $ 48.0 million in proceeds received pursuant to the gilead agreement and offset by $ 31.1 million in revenue recognized pursuant to the celgene agreement and the gilead agreement and an increase in accrued and other liabilities of $ 2.4 million primarily related to an increase in accrued compensation from higher incentive compensation .
```    
 Suspicious Activity Report : we evaluate each contingent payment on an individual basis to determine whether they are considered substantive milestones , specifically reviewing factors such as the degree of certainty in achieving the milestone , the research and development risk and other risks that must be overcome to achieve the milestone , as well as the level of effort and investment required and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement . this evaluation includes an assessment of whether ( a ) the consideration is commensurate with either ( 1 ) the entity 's performance to achieve the milestone , or ( 2 ) the enhancement of the value of the delivered item ( s ) as a result of a specific outcome resulting from the entity 's performance to achieve the milestone , ( b ) the consideration relates solely to past performance and ( c ) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement . revenues from milestones , if they are nonrefundable and deemed substantive , are recognized upon achievement of the milestones . to the extent that non-substantive milestones are achieved , and we have remaining deliverables , milestone payments are deferred and recognized as revenue over the estimated remaining performance period using the appropriate measure of progress as determined for each agreement . we recognize revenue associated with the non-substantive milestones upon achievement of the milestone if we have no remaining deliverables . during the years ended november 30 , 2019 , no milestone payments were received , no milestone revenues were recognized and no milestones were considered substantive . effective december 1 , 2019 , we adopted topic 606 , revenue from contracts with customers using the modified retrospective method , which was only applied to contracts that were not completed as of the adoption date . as of the adoption date , we had only one contract , a collaboration agreement with gilead , not completed . under topic 606 , we recognize revenue when its customer obtains control of promised goods or services , in an amount that reflects the consideration which we expect to receive in exchange for those goods or services . to determine revenue recognition for arrangements that we determine are within the scope of topic 606 , we perform the following five steps : ( i ) identify the contract ( s ) with a customer ; ( ii ) identify the performance obligations in the contract ; ( iii ) determine the transaction price ; ( iv ) allocate the transaction price to the performance obligations in the contract ; and ( v ) recognize revenue when ( or as ) we satisfy a performance obligation . 102 at contract inception , we assess the goods or services promised within each contract , whether each promised good or service is distinct , and determines those that are performance obligations . we then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied . we enter into collaboration agreements under which we may obtain upfront payments , milestone payments , royalty payments and other fees . promises under these arrangements may include research licenses , research services , including selection campaign research services for certain replacement targets , the obligation to share information during the research and the participation of alliance managers and in joint research committees , joint patent committees and joint steering committees . we assess these promises within the context of the agreements to determine the performance obligations . research and collaboration licenses : if a license is determined to be distinct from the other promises identified in the arrangement , we recognize revenue from upfront payments allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license . for licenses that are bundled with other promises , we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and , if over time , the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable , upfront payments . we evaluate the measure of proportional performance each reporting period and , if necessary , adjusts the measure of performance and related revenue recognition . milestone payments : at the inception of each arrangement that includes research , development , or regulatory milestone payments , we evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price . we use the most likely amount method for research , development and regulatory milestone payments . under the most likely amount method , an entity considers the single most likely amount in a range of possible consideration amounts . if it is probable that a significant revenue reversal would not occur , the associated milestone amount is included in the transaction price . sales-based milestones and royalties : for arrangements that include sales-based milestone or royalty payments based on the level of sales , and in which the license is deemed to be the predominant item to which the sales-based milestone or royalties relate to , we recognize revenue in the period in which the sales-based milestone is achieved and in the period in which the sales associated with the royalty occur . to date , we have not recognized any sales-based milestone or royalty revenue resulting from our collaboration arrangements . customer options : customer options , such as options granted to allow a licensee to extend a license or research term , to select additional research targets or to choose to research , develop and commercialize licensed compounds are evaluated at contract inception to determine whether those options provide a material right ( story_separator_special_tag we evaluate each contingent payment on an individual basis to determine whether they are considered substantive milestones , specifically reviewing factors such as the degree of certainty in achieving the milestone , the research and development risk and other risks that must be overcome to achieve the milestone , as well as the level of effort and investment required and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement . this evaluation includes an assessment of whether ( a ) the consideration is commensurate with either ( 1 ) the entity 's performance to achieve the milestone , or ( 2 ) the enhancement of the value of the delivered item ( s ) as a result of a specific outcome resulting from the entity 's performance to achieve the milestone , ( b ) the consideration relates solely to past performance and ( c ) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement . revenues from milestones , if they are nonrefundable and deemed substantive , are recognized upon achievement of the milestones . to the extent that non-substantive milestones are achieved , and we have remaining deliverables , milestone payments are deferred and recognized as revenue over the estimated remaining performance period using the appropriate measure of progress as determined for each agreement . we recognize revenue associated with the non-substantive milestones upon achievement of the milestone if we have no remaining deliverables . during the years ended november 30 , 2019 , no milestone payments were received , no milestone revenues were recognized and no milestones were considered substantive . effective december 1 , 2019 , we adopted topic 606 , revenue from contracts with customers using the modified retrospective method , which was only applied to contracts that were not completed as of the adoption date . as of the adoption date , we had only one contract , a collaboration agreement with gilead , not completed . under topic 606 , we recognize revenue when its customer obtains control of promised goods or services , in an amount that reflects the consideration which we expect to receive in exchange for those goods or services . to determine revenue recognition for arrangements that we determine are within the scope of topic 606 , we perform the following five steps : ( i ) identify the contract ( s ) with a customer ; ( ii ) identify the performance obligations in the contract ; ( iii ) determine the transaction price ; ( iv ) allocate the transaction price to the performance obligations in the contract ; and ( v ) recognize revenue when ( or as ) we satisfy a performance obligation . 102 at contract inception , we assess the goods or services promised within each contract , whether each promised good or service is distinct , and determines those that are performance obligations . we then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied . we enter into collaboration agreements under which we may obtain upfront payments , milestone payments , royalty payments and other fees . promises under these arrangements may include research licenses , research services , including selection campaign research services for certain replacement targets , the obligation to share information during the research and the participation of alliance managers and in joint research committees , joint patent committees and joint steering committees . we assess these promises within the context of the agreements to determine the performance obligations . research and collaboration licenses : if a license is determined to be distinct from the other promises identified in the arrangement , we recognize revenue from upfront payments allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license . for licenses that are bundled with other promises , we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and , if over time , the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable , upfront payments . we evaluate the measure of proportional performance each reporting period and , if necessary , adjusts the measure of performance and related revenue recognition . milestone payments : at the inception of each arrangement that includes research , development , or regulatory milestone payments , we evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price . we use the most likely amount method for research , development and regulatory milestone payments . under the most likely amount method , an entity considers the single most likely amount in a range of possible consideration amounts . if it is probable that a significant revenue reversal would not occur , the associated milestone amount is included in the transaction price . sales-based milestones and royalties : for arrangements that include sales-based milestone or royalty payments based on the level of sales , and in which the license is deemed to be the predominant item to which the sales-based milestone or royalties relate to , we recognize revenue in the period in which the sales-based milestone is achieved and in the period in which the sales associated with the royalty occur . to date , we have not recognized any sales-based milestone or royalty revenue resulting from our collaboration arrangements . customer options : customer options , such as options granted to allow a licensee to extend a license or research term , to select additional research targets or to choose to research , develop and commercialize licensed compounds are evaluated at contract inception to determine whether those options provide a material right (

